BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36703939)

  • 1. Upregulation of NDUFAF2 in Lung Adenocarcinoma Is a Novel Independent Prognostic Biomarker.
    Zou K; Gao P; Xu X; Zhang W; Zeng Z
    Comput Math Methods Med; 2023; 2023():2912968. PubMed ID: 36703939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():724741. PubMed ID: 34335635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma.
    Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ
    Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of PTGES3 is an independent predictive poor prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma.
    Gao P; Zou K; Xiao L; Zhou H; Xu X; Zeng Z; Zhang W
    Int Immunopharmacol; 2022 Sep; 110():108954. PubMed ID: 35820363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.
    Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J
    Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated analyzes identify CCT3 as a modulator to shape immunosuppressive tumor microenvironment in lung adenocarcinoma.
    Huang J; Hu B; Yang Y; Liu H; Fan X; Zhou J; Chen L
    BMC Cancer; 2023 Mar; 23(1):241. PubMed ID: 36918801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma.
    Chen R; Wang Z; Lu T; Liu Y; Ji Y; Yu Y; Tou F; Guo S
    Thorac Cancer; 2023 Apr; 14(10):893-912. PubMed ID: 36825773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma.
    Liu W; Du Q; Mei T; Wang J; Huang D; Qin T
    BMC Cancer; 2024 Jan; 24(1):94. PubMed ID: 38233752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics.
    Chen C; Tang Y; Qu WD; Han X; Zuo JB; Cai QY; Xu G; Song YX; Ke XX
    BMC Cancer; 2021 May; 21(1):619. PubMed ID: 34039308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.
    Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R
    Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma.
    Feng W; He Z; Shi L; Zhu Z; Ma H
    Biochem Genet; 2023 Oct; 61(5):1937-1966. PubMed ID: 36892747
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Zheng X; Han L; Guan J; Chen C; Zhang Y; Zhang J; Zhang Y; Liu S; Su J; Liu M; Huang H
    Front Oncol; 2023; 13():1274439. PubMed ID: 38152367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STARD12/14 are diagnostic and prognostic biomarkers of lung adenocarcinoma associated with epigenetic regulation, immune infiltration and ferroptosis.
    Zhang WD; Hu DM; Shi ZE; Wang QX; Zhang MY; Liu JY; Ji XL; Qu YQ
    Int J Med Sci; 2023; 20(11):1427-1447. PubMed ID: 37790851
    [No Abstract]   [Full Text] [Related]  

  • 15. Cancer/testis antigen HEMGN correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma.
    Jiang Y; Yu L; Hu Q; Kang Y; You J; Huang C; Xu X; Chen L
    Mol Immunol; 2023 Jan; 153():226-237. PubMed ID: 36563642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation.
    Li Z; Hu M; Qiu J; Feng J; Zhang R; Wu H; Hu G; Ren J
    Med Sci Monit; 2022 Jan; 28():e933447. PubMed ID: 35027526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and immunological potential of PPM1G in lung adenocarcinoma.
    Yin R; Qu L; Wang Z; Tang J; Gu H; Wang X; Yang D; Du P; Dong M
    Mol Med Rep; 2023 Aug; 28(2):. PubMed ID: 37387407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAIP serves as a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma.
    Jing Y; Mao Z; Zhu J; Ma X; Liu H; Chen F
    Int Immunopharmacol; 2023 Sep; 122():110605. PubMed ID: 37451021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma.
    Ma C; Kang W; Yu L; Yang Z; Ding T
    Front Oncol; 2020; 10():590006. PubMed ID: 33363020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDCA4 as a novel molecular biomarker of poor prognosis in patients with lung adenocarcinoma.
    Tan J; Chen F; Ouyang B; Li X; Zhang W; Gao X
    Front Oncol; 2022; 12():865756. PubMed ID: 36185189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.